labetalol has been researched along with Liver Cirrhosis in 6 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Long term administration of isosorbide dinitrate also had a significant effect (p less than 0." | 2.66 | Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis. ( Barton, JR; Freeman, JG; Record, CO, 1985) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model." | 1.37 | Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011) |
| " The lack of an adverse outcome in this patient does not prove the safety of this technique in patients with liver disease; further studies of this patient group are required." | 1.27 | Safe use of induced hypotension in a patient with cirrhotic liver disease. ( Roth, S; Run, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 2 |
| Robertson, TA | 2 |
| Thorling, CA | 1 |
| Zhang, Q | 2 |
| Fletcher, LM | 2 |
| Crawford, DH | 2 |
| Roberts, MS | 2 |
| Nair, G | 1 |
| Hema Sree, GNS | 1 |
| Saraswathy, GR | 1 |
| Marise, VLP | 1 |
| Krishna Murthy, TP | 1 |
| Weiss, M | 1 |
| Ljubicić, N | 1 |
| Bilić, A | 1 |
| Roth, S | 1 |
| Run, S | 1 |
| Freeman, JG | 1 |
| Barton, JR | 1 |
| Record, CO | 1 |
2 trials available for labetalol and Liver Cirrhosis
| Article | Year |
|---|---|
The effects of selective and non-selective adrenoceptor blockade on the portal blood flow in patients with liver cirrhosis.
Topics: Adult; Analysis of Variance; Atenolol; Blood Flow Velocity; Female; Humans; Labetalol; Liver Cirrhos | 1991 |
Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
Topics: Humans; Hypertension, Portal; Isosorbide Dinitrate; Labetalol; Liver Cirrhosis; Venous Pressure; Ver | 1985 |
4 other studies available for labetalol and Liver Cirrhosis
| Article | Year |
|---|---|
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cations; Cytochrome P-450 | 2011 |
Application of comprehensive bioinformatics approaches to reconnoiter crucial genes and pathways underpinning hepatocellular carcinoma: a drug repurposing endeavor.
Topics: Carcinoma, Hepatocellular; Cdc20 Proteins; Computational Biology; Drug Repositioning; Humans; Labeta | 2021 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Safe use of induced hypotension in a patient with cirrhotic liver disease.
Topics: Adult; Anesthesia, General; Female; Humans; Hypotension, Controlled; Intracranial Aneurysm; Labetalo | 1987 |